OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

GDC Releases Harmonized Genomic Data From CPTAC

Data Release-20 from the Genomic Data Commons (GDC) includes genomics from a new CPTAC project!  


CPTAC Researchers Reveal Novel Biological Features of Kidney Clear Cell Carcinoma

Investigators with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) have generated the most comprehensive multi-omics dataset for clear cell renal cell carcinoma (ccRCC), the most commonly diagnosed kidney cancer subtype. The investigators...


CPTAC Scientific Symposium 2019 – Great Beginnings!

Over three hundred proteomic explorers and  Clinical Proteomics Tumor Analysis Consortium (CPTAC) participants from around the country convened on the NIH Bethesda campus to share cutting-edge proteogenomic research in the first ever,...


One Computational Step in the Journey to Identify Biological Pathways in Cancer

Large multi-omics datasets are becoming increasingly popular for studying biological systems including the identification of biological pathways, or more broadly defined gene sets, that are associated with certain biological or clinical features of interest.


ICPC China Team Comprehensively Characterizes HBV Related Liver Cancer

Hepatocellular carcinoma (HCC), the most common form of liver cancer, occurs most often in people with hepatitis B or C viral (HBV or HCV) infections who drink large amounts of alcohol.  Unlike the recent progress of antiviral-eliminating therapy...


CPTAC Teams Up With UniProt!

UniProt, the leading online protein reference library, has teamed up with CPTAC!  Now, search results for your protein-of-interest will include links to the CPTAC Assay Portal for relevant peptides and assay protocols, while giving CPTAC users all the rich functional annotation in...


CPTAC Researchers Develop Novel RAS-Antibodies for the Cancer Research Community through the NCI RAS-Initiative

RAS gene mutations and their pathways have  stymied cancer researchers for decades.  RAS-driven cancers make up more than 30% of all human cancers due to their association with uncontrollable cell growth, death-signal...


cBioPortal Gets a New Addition: CPTAC Researchers Integrate Mass-Spectrometry Data Into Genomic Platform

Genomics platform cBioPortal offers a “biologist-friendly” resource for querying mutations, copy number variations and gene expression. It contains data from The...


Multi-Omics Data Integration Special Issue Features Research from CPTAC Investigators

The Journal of Molecular & Cellular Proteomics has released a special issue this month (August 2019) on Multi-Omics Integration.  The issue sets out to show how multi-omics research is integral to the understanding of biological...


More Validated Targeted MS-based Assays Released on the NCI Proteomics Assay Portal!

New assays have been released today!  CPTAC and researchers from the University of Victoria – Genome British Columbia Proteomics Centre just released over 130 quantitative, fit-for-purpose, multiplexed mouse multiple reaction monitoring (MRM) mass spectrometry (MS)-based  plasma assays for...


Pages